3
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Adherence to treatment with adalimumab, golimumab and ustekinumab in patients with inflammatory bowel disease Translated title: Adherencia al tratamiento con adalimumab, golimumab y ustekinumab en pacientes con enfermedad inflamatoria intestinal

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Abstract Objective: Inflammatory bowel disease comprises a group of chronic relapsing inflammatory disorders affecting the bowel. In the last decade, the advent of biological drugs brought about a drastic change in the treatment of the disease. Adalimumab, golimumab and ustekinumab are three biologic agents that patients can self-administer subcutaneously after collecting them from the pharmacy department. However, for the treatment to be effective, adherence is paramount. The purpose of the present study is to evaluate adherence in patients who collected all three drugs from the dispensary of a tertiary care hospital. Method: A cross-sectional observational analysis was carried out of patients who had been receiving treatment with adalimumab, golimumab and ustekinumab for at least four months. The medication possession ratio was calculated based on information extracted from the pharmacy dispensing records. Patients with a ratio < 85% were enrolled in the study and asked to respond to Morisky-Green Medication Adherence Questionnaire. Results: One-hundred and seventy-eight patients were included, of whom 60.1% (107) were male and 30.9% (55) had been treated pre viously with other biologics. According to the pharmacy dispensing re cords, mean adherence was 91.79%, with 45 patients (25.28%) classified as scarcely compliant (< 85%). The Morisky-Green Medication Adherence Questionnaire revealed that carelessness about administering the drug at the right time and forgetfulness were the main reasons for therapeutic non-adherence. Female sex (odds ratio 0.42; p = 0.013) and lengthy treatments (p = 0.002) were associated to lower adherence rates. Conclusions: Although most patients in the studied population were seen to be compliant, low levels of adherence were observed in a number of patients who would benefit from interventions aimed at boosting their adherence. It must be said, however, that the statistical power of this study should be enhanced in order to increase the significance of the results obtained.

          Translated abstract

          Resumen Objetivo: La enfermedad inflamatoria intestinal es un grupo de trastor nos crónicos, inflamatorios y recidivantes que afectan al intestino. En la última década, los fármacos biológicos han supuesto un gran cambio en la terapia de esta enfermedad. Adalimumab, golimumab y ustekinumab son tres de ellos que se administran por vía subcutánea tras su dispensa ción en los servicios de farmacia de los hospitales. Para que se alcance la efectividad del tratamiento es necesaria una adecuada adherencia al mismo. El objetivo del presente trabajo fue evaluar la adherencia en pacientes que recogían los tres fármacos en el servicio de farmacia de un hospital de tercer nivel. Método: Se realizó un estudio analítico observacional de corte trans versal en el que se incluyó a pacientes que recibían tratamiento con los anteriores fármacos durante al menos cuatro meses. Se recogió la tasa de posesión de la medicación proporcionada por el registro de dispen saciones y se seleccionó a los pacientes que presentaron un valor inferior o igual al 85%. A estos pacientes se les aplicó el cuestionario de medida del cumplimiento terapéutico de Morisky-Green. Resultados: Se incluyeron 178 pacientes, de los cuales el 60,1% (107) fueron hombres y el 30,9% (55) habían sido tratados con otros fárma cos biológicos previamente. La adherencia media, según el registro de dispensaciones, fue del 91,79% y se clasificó a 45 pacientes (25,28%) como mal adherentes (< 85%). La no administración en la fecha indica da y el olvido se identificaron como principales razones de la falta de cumplimiento terapéutico según el resultado del test de Morisky-Green. El sexo femenino (odds ratio 0,42; p = 0,013) y la duración del tratamiento (p = 0,002) se asociaron a una peor adherencia a la medicación. Conclusiones: El porcentaje de adherencia obtenido resultó elevado en la población de estudio, pero se identificaron pacientes mal cumpli dores susceptibles de recibir intervenciones para mejorar su adherencia. No obstante, se debería aumentar la potencia estadística para mejorar la validez de los resultados obtenidos.

          Related collections

          Most cited references24

          • Record: found
          • Abstract: not found
          • Article: not found

          Adherence to long-term therapies: evidence for action.

            Bookmark
            • Record: found
            • Abstract: found
            • Article: found

            A Systematic Review of Factors Associated with Non-Adherence to Treatment for Immune-Mediated Inflammatory Diseases

            Background Non-adherence impacts negatively on patient health outcomes and has associated economic costs. Understanding drivers of treatment adherence in immune-mediated inflammatory diseases is key for the development of effective strategies to tackle non-adherence. Objective To identify factors associated with treatment non-adherence across diseases in three clinical areas: rheumatology, gastroenterology, and dermatology. Design Systematic review. Data Sources Articles published in PubMed, Science Direct, PsychINFO and the Cochrane Library from January 1, 1980 to February 14, 2014. Study Selection Studies were eligible if they included patients with a diagnosis of rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, inflammatory bowel disease, or psoriasis and included statistics to examine associations of factors with non-adherence. Data Extraction Data were extracted by the first reviewer using a standardized 23-item form and verified by a second/third reviewer. Quality assessment was carried out for each study using a 16-item quality checklist. Results 73 studies were identified for inclusion in the review. Demographic or clinical factors were not consistently associated with non-adherence. Limited evidence was found for an association between non-adherence and treatment factors such as dosing frequency. Consistent associations with adherence were found for psychosocial factors, with the strongest evidence for the impact of the healthcare professional–patient relationship, perceptions of treatment concerns and depression, lower treatment self-efficacy and necessity beliefs, and practical barriers to treatment. Conclusions While examined in only a minority of studies, the strongest evidence found for non-adherence were psychosocial factors. Interventions designed to address these factors may be most effective in tackling treatment non-adherence. Electronic supplementary material The online version of this article (doi:10.1007/s12325-015-0256-7) contains supplementary material, which is available to authorized users.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Adherence to anti-TNF therapy in inflammatory bowel diseases: a systematic review.

              Nonadherence to medications may affect disease outcomes. The aim of this article was to review methods of assessment, prevalence, and predictors of nonadherence to anti-tumor necrosis factor therapy in inflammatory bowel diseases (IBD).
                Bookmark

                Author and article information

                Journal
                fh
                Farmacia Hospitalaria
                Farm Hosp.
                Grupo Aula Médica (Toledo, Toledo, Spain )
                1130-6343
                2171-8695
                April 2020
                : 44
                : 2
                : 62-67
                Affiliations
                [2] Navarra orgnameUniversidad Pública de Navarra orgdiv1School of Health Sciences Spain
                [1] Navarra orgnameUniversidad Pública de Navarra orgdiv1Pharmacy Department Spain
                Article
                S1130-63432020000200062 S1130-6343(20)04400200062
                10.7399/fh.11325
                016688eb-1d3a-43d9-8a67-fbcb936963fd

                This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

                History
                : 16 December 2019
                : 13 September 2019
                Page count
                Figures: 0, Tables: 0, Equations: 0, References: 30, Pages: 6
                Product

                SciELO Spain

                Categories
                Originals

                Golimumab,Ustekinumab,Enfermedad inflamatoria intestinal,Adalimumab,Therapeutic adherence,Biological therapy,Terapia biológica,Adherencia terapéutica,Inflammatory bowel disease

                Comments

                Comment on this article